Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, will be collaborating with investigators at the University of California, San Francisco (USCF), on a clinical study to evaluate the use and performance of technetium–labeled tilmanocept in patients with Kaposi Sarcoma (KS). The investigator–initiated study will evaluate HIV patients with various stages of KS who will be administered 99mTc-tilmanocept and assessed by SPECT imaging for localization of KS lesions and possible identification of KS disease spread.
Co-primary investigators are Michael S McGrath, MD, PhD, professor, Departments of Laboratory Medicine, Pathology, and Medicine, UCSF, and Toby Maurer, MD, dermatologist, UCSF Lakeshore Family Medicine Centre.
“Kaposi sarcoma not only affects skin but in more advanced states involves other organs and tissues, including lymph nodes. Attempts to confirm KS involvement in other tissues to determine if and where the tumor has spread have generally been problematic, so patient staging and treatment regimens may not be optimally managed,” commented Dr McGrath. “The receptor-targeting properties and strong performance in malignancies such as melanoma and breast cancer indicate that tilmanocept and other Manocept-derived agents which specifically target the CD206 mannose receptor are potentially potent tools for addressing unmet needs in this area such as identifying, staging and assessing disease activity.”
Navidea also announced that results from a study of Kaposi sarcoma (KS) tissue, using a novel fluorescent imaging agent from the Company’s Manocept Platform, were presented at the 14th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI) by Dr McGrath at the National Institutes of Health (NIH) in Bethesda, Maryland.
“This conference presentation further emphasized the potential of our Manocept platform into therapeutic areas where there is medical need for innovative precision diagnostics in the quest for better patient outcomes,” said Frederick Cope, PhD, FACN, senior vice president and chief scientific officer at Navidea. “These newly developed data suggest that our Manocept platform represents an opportunity to exploit the CD206-targeting mechanism underlying the robust, purpose-built drug design of our approved lymphatic mapping agent. With the announcement of our exciting UCSF clinical collaboration, we intend to continue to evaluate emerging data in KS and will further explore other disease states to refine our areas of focus and capitalize on this innovative platform."